Qiagen closes NeuMoDx deal

By LabPulse.com staff writers

September 18, 2020 -- Qiagen has acquired the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular for $248 million in cash. The deal rounds out Qiagen's portfolio of automated molecular testing based on polymerase chain reaction (PCR) technology.

In 2018, Qiagen purchased a 19.9% stake in NeuMoDx along with the right to acquire the remaining NeuMoDx stake at a price of $234 million. The final price for the remaining stake includes customary purchase price adjustments for cash, indebtedness, and transaction costs.

Also, as part of the deal, Qiagen has distributed the high-throughput NeuMoDx 288 and the medium-throughput NeuMoDx 96 in Europe and other markets.

Integrating NeuMoDx will allow Qiagen to address laboratory needs in almost any setting for molecular diagnostics, the firm said.

Qiagen to launch rapid portable SARS-CoV-2 antigen test
Qiagen plans to launch the Access Anti-SARS-CoV-2 antigen test, a rapid portable test that can detect novel coronavirus antigens in people with active...
Qiagen launches 10-minute SARS-CoV-2 test
Qiagen announced the U.S. launch of a new digital SARS-CoV-2 detection test that can be done on a portable device. The device provides results in about...
Qiagen appoints new supervisory board chairman
Qiagen has appointed Lawrence Rosen as the new chairman of its supervisory board, effective immediately. The news comes in the wake of the failure of...
Thermo Fisher's acquisition of Qiagen falls short
Thermo Fisher Scientific has terminated its acquisition of Qiagen after the company was unable to secure the number of shares needed to proceed with the...
Thermo Fisher increases Qiagen acquisition offer
Thermo Fisher Scientific and Qiagen have amended their acquisition agreement with an increase from the original offer price of 39 euros ($44.61 U.S.)...

Copyright © 2020 LabPulse.com

Last Updated ls 9/18/2020 5:10:46 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email